Boston Scientific, a Marlborough medical device manufacturer, has entered into yet another half-billion-dollar purchase agreement, this time to acquire Nalu Medical, a California-based medical technology firm creating solutions for chronic nerve pain.
Boston Scientific, a Marlborough medical device manufacturer, has entered into yet another half-billion-dollar purchase agreement, this time to acquire Nalu Medical, a California-based medical technology firm creating solutions for chronic nerve pain.
Already an investor in Nalu, Boston Scientific’s acquisition will see the manufacturer purchase Nalu’s remaining equity for approximately $533 million, according to a Friday press release.
As part of the purchase, Boston Scientific will add Nalu’s neurostimulation system to its portfolio: a pain treatment that disrupts the body’s pain signals before they reach the brain through an implantable pulse generator releasing mild electrical impulses.
The treatment is designed for adults with severe and obstinate chronic pain, such as in the shoulders, lower back and knees, stemming from the peripheral nerves.
"Peripheral nerve stimulation is an exciting field with a significant unmet patient need," Jim Cassidy, president, neuromodulation at Boston Scientific, said in the release. "Adding the highly differentiated Nalu Medical technology complements our existing therapies, including spinal cord stimulation, basivertebral nerve ablation, and radiofrequency ablation, enabling us to deliver advanced pain relief options to a wider variety of patient populations."
Nalu’s Neurostimulation System received U.S. Food and Drug Administration 510(k) clearance in 2019.
Separate from an FDA approval, a 510(k) clearance is an authorization confirming a product is substantially equivalent to a legally marketed device, and thus, can be sold in the U.S. market, according to the FDA’s website. Obtaining a 510(k) clearance means a product does not have to go through the FDA’s approval process.
Boston Scientific expects to complete the acquisition in the first half of 2026. The manufacturer does not anticipate the purchase will affect its adjusted earnings per share next year, but does foresee it being slightly accretive in 2027, and more so thereafter.
Boston Scientific’s latest definitive agreement follows a string of acquisitions the firm has completed in the past year.
In November, the company announced
it would acquire Cortex, a California medical technology company, and
Intera Oncology, a Newton-based medical device company.
In January, Boston Scientific announced it would purchase California-based
medical equipment manufacturer Bolt Medical for $443 million, and later in March, it entered into a purchase agreement to acquire Israel-based
medical device company SoniVie for up to $540 million.
Mica Kanner-Mascolo is a staff writer at Worcester Business Journal, who primarily covers the healthcare and diversity, equity, and inclusion industries.
